ArticleFrontiers of medicine2025
Yinqiao powder effectively alleviates acute lung injury via regulating cGAS-STING signaling pathway.
Article in Frontiers of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) is a respiratory disease characterized by inflammation. Yinqiao powder (YQP) is a traditional Chinese medicinal compound, extensively used for its heat-clearing and detoxifying effects. It is usually used clinically to treat respiratory diseases, such as pneumonia. However, the exact mechanism by which YQP treats ALI remains unclear. Here, we aimed to explore the therapeutic effects and potential mechanisms of action of YQP in ALI. Activation of the cGAS-STING pathway was modeled by multiple stimuli in bone marrow-derived macrophages (BMDMs), THP-1, and peripheral blood mononuclear cells (PBMCs). Changes in the content of associated proteins were detected by Western blot, while the mRNA levels of type I interferon-related genes and proinflammatory cytokines were detected by qPCR. A DMXAA-induced agonist model was used to verify the effect of YQP on the cGAS-STING pathway in vivo, whereas LPS-induced ALI was used to explore the therapeutic effect of YQP. YQP suppressed the activation of the cGAS-STING pathway in vitro. YQP showed promising therapeutic effects on DMXAA-induced activation of the cGAS-STING signaling pathway as well as the LPS-induced ALI model in mice. YQP alleviated ALI by inhibiting cGAS-STING pathway activation; meanwhile, YQP may be a new therapeutic approach for cGAS-STING-driven inflammatory diseases.
Indexed as
Identifiers
41454071What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.